UnitedHealth Group — Jul 16, 2026 release

• Launched the industry’s first fully transparent, fee-based pharmacy care model to bring greater clarity, predictability and affordability by decoupling PBM pricing from drug list prices and prescription volume, aligning incentives with patients and plan sponsors and introducing digital tools that allow consumers to view and compare medication costs upfront. • Committed to 100% pass-through of manufacturer drug rebate discounts to clients by January 1, 2028. • Eliminated 33% of drug reauthorizations – representing 11% of pharmacy prior approvals – for a list of nearly 270 chronic condition medications. • Increased minimum payments to independent and community physicians for brand name drugs, benefitting approximately 2,300 independent and community pharmacies.   Page 4 of 17 UnitedHealth Group Second Quarter 2026 Results Quarterly Financial Performance Three Months Ended June 30, 2026 June 30, 2025 March 31, 2026 Revenues $112.0 billion $111.6 billion $111.7 billion Earnings from Operations $8.0 billion $5.2 billion $9.0 billion Net Margin 4.9% 3.1% 5.6% • UnitedHealth Group’s second quarter 2026 revenues were $112.0 billion compared to $111.6 billion in the year ago quarter. • Second quarter 2026 earnings from operations of $8.0 billion compared to $5.2 billion in the year ago quarter, driven by strong performance across both UnitedHealthcare and Optum. • The second quarter 2026 medical care ratio was 86.7% compared to 89.4% in the second quarter 2025. The year-over-year decrease was driven by benefit design and pricing discipline, member